Literature DB >> 26300492

Stabilization of MCRS1 by BAP1 prevents chromosome instability in renal cell carcinoma.

Jingtao Peng1, Jian Ma1, Weiguo Li1, Ren Mo2, Pingzhao Zhang3, Kun Gao3, Xiaofeng Jin3, Jiantao Xiao1, Chenji Wang4, Jie Fan5.   

Abstract

Characterization of the exome and genome of carcinoma (ccRCC) by next-generation sequencing identified numerous genetic alternations. BRCA1-associated protein-1 (BAP1) was identified as one of the most frequently mutated genes in ccRCC, suggesting that BAP1 is a potential key driver for ccRCC cancer initiation and progression. However, how BAP1 mutations contribute to ccRCC remains to be elucidated. BAP1 is a nuclear de-ubiquitinating enzyme and cleaves the ubiquitin chain from the substrates. Here, we identified MCRS1 as a bona fide substrate for BAP1. MCRS1 is a component of the centrosome proteins, and plays an essential role in spindle assembly. BAP1 binds to MCRS1 and stabilizes MCRS1 by de-ubiquitination. BAP1 contributes to chromosome stability partially via MCRS1. A positive correlation was identified between BAP1 and MCRS1 expression in ccRCC tissues. Both BAP1 loss and MCRS1 down-regulation in ccRCC were associated with adverse clinicopathological features. This study revealed a novel mechanism for BAP1 involved in MCRS1 stability regulation, and provided insight in understanding the relationship between BAP1 mutations and chromosome instability in ccRCC.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  BAP1; Chromosome instability; Clear cell renal cell carcinoma; De-ubiquitination; MCRS1

Mesh:

Substances:

Year:  2015        PMID: 26300492     DOI: 10.1016/j.canlet.2015.08.013

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  14 in total

1.  BAP1 promotes the repair of UV-induced DNA damage via PARP1-mediated recruitment to damage sites and control of activity and stability.

Authors:  Shin-Ai Lee; Daye Lee; Minhwa Kang; Sora Kim; Su-Jung Kwon; Han-Sae Lee; Hye-Ran Seo; Prashant Kaushal; Nam Soo Lee; Hongtae Kim; Cheolju Lee; Jongbum Kwon
Journal:  Cell Death Differ       Date:  2022-05-30       Impact factor: 15.828

2.  BAP1 maintains HIF-dependent interferon beta induction to suppress tumor growth in clear cell renal cell carcinoma.

Authors:  Lauren E Langbein; Rayan El Hajjar; Shen He; Eleonora Sementino; Zhijiu Zhong; Wei Jiang; Benjamin E Leiby; Li Li; Robert G Uzzo; Joseph R Testa; Haifeng Yang
Journal:  Cancer Lett       Date:  2022-08-20       Impact factor: 9.756

3.  MCRS1 Expression Regulates Tumor Activity and Affects Survival Probability of Patients with Gastric Cancer.

Authors:  Liang-Han Wang; Chih-Chun Chang; Chiao-Yin Cheng; Yao-Jen Liang; Dee Pei; Jen-Tang Sun; Yen-Lin Chen
Journal:  Diagnostics (Basel)       Date:  2022-06-20

Review 4.  Roles of the BAP1 Tumor Suppressor in Cell Metabolism.

Authors:  Anna Han; Timothy J Purwin; Andrew E Aplin
Journal:  Cancer Res       Date:  2021-01-14       Impact factor: 13.312

5.  Aggressive uveal melanoma displays a high degree of centrosome amplification, opening the door to therapeutic intervention.

Authors:  Dorota Sabat-Pośpiech; Kim Fabian-Kolpanowicz; Helen Kalirai; Natalie Kipling; Sarah E Coupland; Judy M Coulson; Andrew B Fielding
Journal:  J Pathol Clin Res       Date:  2022-04-26

6.  Germline BAP1 mutations induce a Warburg effect.

Authors:  Angela Bononi; Haining Yang; Carlotta Giorgi; Simone Patergnani; Laura Pellegrini; Mingming Su; Guoxiang Xie; Valentina Signorato; Sandra Pastorino; Paul Morris; Greg Sakamoto; Shafi Kuchay; Giovanni Gaudino; Harvey I Pass; Andrea Napolitano; Paolo Pinton; Wei Jia; Michele Carbone
Journal:  Cell Death Differ       Date:  2017-06-30       Impact factor: 15.828

7.  Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal.

Authors:  Samra Turajlic; Hang Xu; Kevin Litchfield; Andrew Rowan; Stuart Horswell; Tim Chambers; Tim O'Brien; Jose I Lopez; Thomas B K Watkins; David Nicol; Mark Stares; Ben Challacombe; Steve Hazell; Ashish Chandra; Thomas J Mitchell; Lewis Au; Claudia Eichler-Jonsson; Faiz Jabbar; Aspasia Soultati; Simon Chowdhury; Sarah Rudman; Joanna Lynch; Archana Fernando; Gordon Stamp; Emma Nye; Aengus Stewart; Wei Xing; Jonathan C Smith; Mickael Escudero; Adam Huffman; Nik Matthews; Greg Elgar; Ben Phillimore; Marta Costa; Sharmin Begum; Sophia Ward; Max Salm; Stefan Boeing; Rosalie Fisher; Lavinia Spain; Carolina Navas; Eva Grönroos; Sebastijan Hobor; Sarkhara Sharma; Ismaeel Aurangzeb; Sharanpreet Lall; Alexander Polson; Mary Varia; Catherine Horsfield; Nicos Fotiadis; Lisa Pickering; Roland F Schwarz; Bruno Silva; Javier Herrero; Nick M Luscombe; Mariam Jamal-Hanjani; Rachel Rosenthal; Nicolai J Birkbak; Gareth A Wilson; Orsolya Pipek; Dezso Ribli; Marcin Krzystanek; Istvan Csabai; Zoltan Szallasi; Martin Gore; Nicholas McGranahan; Peter Van Loo; Peter Campbell; James Larkin; Charles Swanton
Journal:  Cell       Date:  2018-04-12       Impact factor: 41.582

8.  EZH2 Expression is increased in BAP1-mutant renal clear cell carcinoma and is related to poor prognosis.

Authors:  Chenmin Sun; Chunchun Zhao; Shugen Li; Jianqing Wang; Qidong Zhou; Jianliang Sun; Qiang Ding; Min Liu; Guanxiong Ding
Journal:  J Cancer       Date:  2018-10-01       Impact factor: 4.207

Review 9.  Clear cell renal cell carcinoma ontogeny and mechanisms of lethality.

Authors:  Eric Jonasch; Cheryl Lyn Walker; W Kimryn Rathmell
Journal:  Nat Rev Nephrol       Date:  2020-11-03       Impact factor: 28.314

10.  Genome doubling shapes the evolution and prognosis of advanced cancers.

Authors:  Craig M Bielski; Ahmet Zehir; Alexander V Penson; Mark T A Donoghue; Walid Chatila; Joshua Armenia; Matthew T Chang; Alison M Schram; Philip Jonsson; Chaitanya Bandlamudi; Pedram Razavi; Gopa Iyer; Mark E Robson; Zsofia K Stadler; Nikolaus Schultz; Jose Baselga; David B Solit; David M Hyman; Michael F Berger; Barry S Taylor
Journal:  Nat Genet       Date:  2018-07-16       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.